Abstract 1195P
Background
Low incidence and heterogeneity of NETs complicates the study of epidemiological and clinical pathways in this population. There is an unmet need for large datasets and BD tools to fill this knowledge gap. Our study aimed to describe the demographic and clinical characteristics of patients with NETs in Spain through the application of BD techniques to EHR.
Methods
This was a retrospective, observational study in adult patients with NETs managed in 5 Spanish centers between 01/01/2014 to 31/12/2019. An unstructured search of free text from EHRs was performed by artificial intelligence (AI) techniques based on SAVANA’s EHRead®, an innovative Natural Language Processing and machine learning system. Patients were included when NET was first identified (Index Date) and classified as `Incident´ or `Prevalent´ if the Index Date was within the study window or not, respectively.
Results
A total of 2,939,309 patients were screened by EHRead and 1,256 NETs cases were found: median age 60y (95% CI 59 - 62), 52% female, 41% with gastroenteropancreatic origin, and 44% were categorized as incident (Table). More than 70% of patients presented symptoms prior to diagnosis and >10% had metastases at diagnosis (>70% were non-resectable). Median time from symptom onset to first diagnosis was 0.6 years (95% CI 0.4 - 0.73). The most frequently detected comorbidities were hypertension (66%), diabetes (35%), asthma (22%), and depression (17%). A previous diagnosis of cancer different from NETs was reported in 21% of cases. Uncommon clinical events included brain metastases (1%) and familial history of NETs (1.1%). Table: 1195P
Classification of patients with NETs
FAS (N=1,256) n (%) | Prevalent (N=700) n (%) | Incident (N=556) n (%) | |
Patients with symptoms before Index Date | 366 (29.1) | 0 (0) | 366 (65.8) |
Primary NET site | |||
Gastroenteropancreatic | 412 (41.4) | 235 (42.7) | 177 (39.7) |
Bronchopulmonary | 171 (17.2) | 81 (14.7) | 90 (20.2) |
Other* | 413 (41.5) | 234 (42.5) | 179 (40.1) |
Classified by surgery at Index Date§ | |||
Thyroidectomy | 9 (0.9) | 3 (0.5) | 6 (1.3) |
Adrenalectomy | 1 (0.1) | 0 (0) | 1 (0.2) |
Other classifications | 1 (0.1) | 1 (0.2) | 0 (0) |
Unclassified NETs | 260 (20.7) | 150 (21.4) | 110 (19.8) |
* Paraganglioma, adrenal gland and medullary thyroid carcinomas and pheochromocytomas§ Within +/-6 months of Index Date
Conclusions
BD Techniques should improve generation of large datasets in low incidence neoplasms and help identify uncommon events. NETs diagnosis is delayed about 6m after symptom onset and comorbidities may influence the choice of treatment.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Content Ed Net (Madrid, Spain)
Legal entity responsible for the study
IPSEN Pharma.
Funding
IPSEN Pharma.
Disclosure
J. Hernando: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13